ClinicalTrials.gg
CompletedNCT04604496Updated Mar 21, 2024Results posted

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

A Phase 1 interventional study of PF-06882961 20MG in Hepatic Impairment and Healthy Volunteers, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961

02

Conditions studied

  • Hepatic Impairment
  • Healthy Volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants between the ages of 18 (or the minimum country-specific age of consent if >18) and 70 years, inclusive, at the screening visit:
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • (BMI) of 17.5 to 38.0 kg/m2, inclusive; and a total body weight >50 kg (110 lb), at the screening visit; with a single repeat assessment of total body weight (and hence BMI), on a separate day permitted to assess eligibility, if needed.

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection); NOTE: Participants who have undergone cholecystectomy and/or appendectomy are eligible for this study as long as the surgery occurred more than 6 months prior to Screening;
  • At screening, participants with a positive result for (HIV) antibodies, as assessed by sponsor-identified central laboratory, with a single repeat permitted to assess eligibility, if needed;
  • A positive COVID-19 test at screening;
  • A diagnosis of type 2 diabetes mellitus (T2DM) that is documented by medical history;
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or participants with suspected MTC per the investigator's judgement;
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study;
  • Use of prior/concomitant therapies
  • Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product used in this study (whichever is longer);
  • Participants with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a study involving PF-06882961;
  • Participants with ANY of the following abnormalities in clinical laboratory tests at Visit 1, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

≥6.5%; FPG ≥126 mg/Dl; \<60 mL/min/1.73m2;

  • A positive urine drug test, for illicit drugs at screening, as assessed by sponsor-identified central laboratory. However, participants in Cohorts 2-4, only, who have been medically prescribed opiates/opioids or benzodiazepines and report the use of these drugs to the investigator at the Screening visit will be allowed to participate; NOTE: repeat urine drug testing is not permitted in this study;
  • At screening or Day -1, a positive breath alcohol test, as assessed using kits provided by sponsor-identified central laboratory, with a single repeat on a separate day permitted to assess eligibility, if needed;
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing and until the follow-up contact; 13. History of sensitivity to heparin or heparin-induced thrombocytopenia, only if heparin is used to flush intravenous catheters used during serial blood collections;
  • Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol;
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PF-06882961 participants without Hepatic Impairment

    This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1

    Drug: PF-06882961 20MG

  • Experimental
    PF-06882961 participants with mild Hepatic Impairment

    This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20MG

  • Experimental
    PF-06882961 participants with moderate Hepatic Impairment

    This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20MG

  • Experimental
    PF-06882961 participants with severe Hepatic Impairment

    This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20MG

Interventions

  • PF-06882961 in 20 mg oral tablet will be administered on Day 1

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Maximum observed plasma PF-06882961 concentration.

    Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.

  2. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)

    Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.

  3. Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)

    Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to the time of the last quantifiable concentration.

    Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.

  4. Fraction of Unbound Drug in Plasma (fu)

    fu = Cu/C (where Cu represents unbound concentration and C represents total concentration).

    Time frame: Predose (0 hours), and 4 hours post dose on Day 1.

Secondary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events (AEs)

    Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. AEs included SAEs and non-serious AEs. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Relatedness to study treatment was determined by the investigator.

    Time frame: Baseline to Day 30

  2. Number of Participants With Clinical Laboratory Abnormalities

    Protocol-required safety laboratory assessments included: hemoglobin \<0.8 x lower limit of normal (LLN), hematocrit \<0.8 x LLN, erythrocytes \<0.8 x LLN, ery. mean corpuscular volume \>1.1 x upper limit of normal (ULN), ery. mean corpuscular hemoglobin \>1.1 x ULN, platelets \<0.5 x LLN, eosinophils \>1.2 x ULN, activated partial thromboplastin time \>1.1 x ULN, prothrombin time \>1.1 x ULN, prothrombin intl. normalized ratio \>1.1 x ULN; bilirubin/direct bilirubin/indirect bilirubin \>1.5 x ULN, aspartate aminotransferase/alanine aminotransferase/gamma glutamyl transferase \>3.0 x ULN, albumin \<0.8 x LLN, urate \>1.2 x ULN, bicarbonate \>1.1 x ULN, triacylglycerol lipase \>1.5 x ULN; urine hemoglobin/urine urobilinogen/urine nitrite/urine leukocyte esterase ≥1.

    Time frame: Baseline to Day 3

  3. Number of Participants With Categorical Vital Signs Data

    Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

    Time frame: Baseline to Day 3

  4. Number of Participants With Categorical Electrocardiogram (ECG) Data

    ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (≥) 300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline

    Time frame: Baseline to Day 3

07

Results

Posted Mar 21, 2024

Participant flow

Open Label Treatment
Participant flow — Open Label Treatment
MilestoneWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Started6666
Completed6666
Not completed0000
Follow-Up
Participant flow — Follow-Up
MilestoneWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Started6666
Completed6666
Not completed0000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)

Maximum observed plasma PF-06882961 concentration.

Time frame:
Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Maximum Plasma Concentration (Cmax)23.56 ± 5031.37 ± 3351.82 ± 8378.73 ± 33
Statistical analysis
  • Without Hepatic Impairment vs Mild Hepatic Impairment · Ratio of adjusted geometric means: 133.17 · 90% CI 81.97 to 216.37
  • Without Hepatic Impairment vs Moderate Hepatic Impairment · Ratio of adjusted geometric means: 219.98 · 90% CI 135.39 to 357.41
  • Without Hepatic Impairment vs Severe Hepatic Impairment · Ratio of adjusted geometric means: 334.21 · 90% CI 205.70 to 543.00
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)

Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)
nanogram*hour per milliliter (ng*hr/mL)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)193.4 ± 83237.3 ± 34546.7 ± 1161239 ± 75
Statistical analysis
  • Without Hepatic Impairment vs Mild Hepatic Impairment · Ratio of adjusted geometric means: 122.70 · 90% CI 61.33 to 245.49
  • Without Hepatic Impairment vs Moderate Hepatic Impairment · Ratio of adjusted geometric means: 282.73 · 90% CI 141.32 to 565.66
  • Without Hepatic Impairment vs Severe Hepatic Impairment · Ratio of adjusted geometric means: 640.78 · 90% CI 320.27 to 1282.00
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)

Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to the time of the last quantifiable concentration.

Time frame:
Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
nanogram*hour per milliliter (ng*hr/mL)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)191.2 ± 84235.0 ± 34542.9 ± 1171217 ± 73
Statistical analysis
  • Without Hepatic Impairment vs Mild Hepatic Impairment · Ratio of adjusted geometric means: 122.89 · 90% CI 61.51 to 245.51
  • Without Hepatic Impairment vs Moderate Hepatic Impairment · Ratio of adjusted geometric means: 283.88 · 90% CI 142.10 to 567.13
  • Without Hepatic Impairment vs Severe Hepatic Impairment · Ratio of adjusted geometric means: 636.32 · 90% CI 318.51 to 1271.24
PrimaryFraction of Unbound Drug in Plasma (fu)

fu = Cu/C (where Cu represents unbound concentration and C represents total concentration).

Time frame:
Predose (0 hours), and 4 hours post dose on Day 1.
Reported as:
Geometric mean · Ratio
Fraction of Unbound Drug in Plasma (fu)
RatioWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Fraction of Unbound Drug in Plasma (fu)0.02137 ± 180.01820 ± 130.02059 ± 210.02889 ± 53
Statistical analysis
  • Without Hepatic Impairment vs Mild Hepatic Impairment · Ratio of adjusted geometric means: 85.19 · 90% CI 63.60 to 114.10
  • Without Hepatic Impairment vs Moderate Hepatic Impairment · Ratio of adjusted geometric means: 96.37 · 90% CI 71.95 to 129.07
  • Without Hepatic Impairment vs Severe Hepatic Impairment · Ratio of adjusted geometric means: 135.20 · 90% CI 100.94 to 181.10
SecondaryNumber of Participants Reporting Treatment-emergent Adverse Events (AEs)

Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. AEs included SAEs and non-serious AEs. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Relatedness to study treatment was determined by the investigator.

Time frame:
Baseline to Day 30
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (AEs)
ParticipantsWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
All-causality0121
Treatment-related0121
SecondaryNumber of Participants With Clinical Laboratory Abnormalities

Protocol-required safety laboratory assessments included: hemoglobin \<0.8 x lower limit of normal (LLN), hematocrit \<0.8 x LLN, erythrocytes \<0.8 x LLN, ery. mean corpuscular volume \>1.1 x upper limit of normal (ULN), ery. mean corpuscular hemoglobin \>1.1 x ULN, platelets \<0.5 x LLN, eosinophils \>1.2 x ULN, activated partial thromboplastin time \>1.1 x ULN, prothrombin time \>1.1 x ULN, prothrombin intl. normalized ratio \>1.1 x ULN; bilirubin/direct bilirubin/indirect bilirubin \>1.5 x ULN, aspartate aminotransferase/alanine aminotransferase/gamma glutamyl transferase \>3.0 x ULN, albumin \<0.8 x LLN, urate \>1.2 x ULN, bicarbonate \>1.1 x ULN, triacylglycerol lipase \>1.5 x ULN; urine hemoglobin/urine urobilinogen/urine nitrite/urine leukocyte esterase ≥1.

Time frame:
Baseline to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities
ParticipantsWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Number of Participants With Clinical Laboratory Abnormalities3456
SecondaryNumber of Participants With Categorical Vital Signs Data

Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

Time frame:
Baseline to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Categorical Vital Signs Data
ParticipantsWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pulse rate value <40 bpm0000
Pulse rate value >120 bpm0000
Sitting DBP value <50 mm Hg0001
Sitting DBP Change ≥ 20 mm Hg increase0021
Sitting DBP Change ≥ 20 mm Hg decrease0000
Sitting SBP value <90 mm Hg0001
Sitting SBP Change ≥ 30 mm Hg increase1000
Sitting SBP Change ≥ 30 mm Hg decrease0000
SecondaryNumber of Participants With Categorical Electrocardiogram (ECG) Data

ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (≥) 300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline

Time frame:
Baseline to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Categorical Electrocardiogram (ECG) Data
ParticipantsWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
PR interval ≥300 msec0000
%Change in PR interval ≥25/50%0001
QRS interval ≥140 msec0000
%Change in QRS interval ≥50%0000
QTcF interval >450 and ≤480 msec0113
QTcF interval >480 and ≤500 msec0000
QTcF interval >500 msec0000
Change in QTcF interval >30 and ≤60 msec0000
Change in QTcF interval >60 msec0000

Adverse events

Collected over Baseline to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Without Hepatic Impairment0/6 (0%)0/6 (0%)0/6 (0%)
Mild Hepatic Impairment0/6 (0%)0/6 (0%)1/6 (16.7%)
Moderate Hepatic Impairment0/6 (0%)0/6 (0%)2/6 (33.3%)
Severe Hepatic Impairment0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventWithout Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
NauseaGastrointestinal disorders0/60/62/61/6
DiarrhoeaGastrointestinal disorders0/61/60/60/6
VomitingGastrointestinal disorders0/60/60/61/6

Baseline characteristics

The baseline analysis population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(Years)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Mean59.3 ± 3.0861.7 ± 5.8557.7 ± 7.1256.2 ± 10.2158.7 ± 6.89
Age, Customized
Age, Customized(Participants)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
45-64 Years635418
>=65 Years03126
Sex: Female, Male
Sex: Female, Male(Participants)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Female323311
Male343313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Hispanic or Latino433313
Not Hispanic or Latino233311
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Without Hepatic ImpairmentMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
White656522
Black or African American00011
Asian01001
08

Study locations

2 sites
  • University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jan 2022, 12 months.

Results were first posted in Mar 2024, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 27, 2020
StartActual
Dec 30, 2020
Primary completionActual
Jan 10, 2022
CompletionActual
Jan 10, 2022
Results first posted
Mar 21, 2024
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04604496
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Dec 30, 2020
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022
Results posted
Mar 21, 2024
Last update
Mar 21, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion